Chemed Posts 3Q EPS of $5.45
CHE sits 39% above its 52-week low of $365.205.
Summary
Chemed reported third-quarter adjusted EPS of $6.75 and net income of $71.6M, alongside EPS of $5.45. The print follows a strong Q2 in which the company beat estimates and raised full-year guidance on VITAS hospice outperformance and heavy buybacks, so the bar was already elevated. The headline carries no revenue, segment detail, or guidance update, so the read-through versus that raised bar is unclear from this alone. Full release and any guidance revision will determine whether the Q2 momentum held.
At the time of this announcement, CHE was trading at $509.09 on NYSE in the Life Sciences sector, with a market capitalization of approximately $6.7B. The 52-week trading range was $365.21 to $557.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.